Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI).

ABSTRACT:

Background

Peripheral biomarkers that identify individuals at risk of developing Alzheimer's disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results.

Methods

The Fundació ACE Healthy Brain Initiative (FACEHBI) study uses a convenience sample of 200 individuals diagnosed with subjective cognitive decline (SCD) at the Fundació ACE (Barcelona, Spain) who underwent amyloid florbetaben(¹⁸F) (FBB) positron emission tomography (PET) brain imaging. Baseline plasma samples from FACEHBI subjects (aged 65.9 ± 7.2 years) were analyzed using the

SUBMITTER: de Rojas I 

PROVIDER: S-EPMC6267075 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature